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Abstract
Our objective was to test the hypothesis that increased GGT predicts an increased
risk of type 2 diabetes (T2D) in elderly Mexican Americans.
Data from a population-based cohort study of 1789 community-dwelling Mexican
American men and women, aged 60-101, in the SALSA study were used. Data for 1,203
participants without diabetes at baseline were evaluated for incident diabetes. Proportional
hazard models were used to predict the probability of incident T2D by GGT level.
After adjustment for age, gender, smoking, alcohol use, and BMI, the risk of
developing T2D associated with GGT was significant at 1.4 (95% CI 1.2 -1.7). However,
when the model was adjusted for fasting serum glucose, the risk was attenuated by 20%, and
the confidence interval included 1.0 (HR 1.1, 95% CI 0.8-1.5).
In conclusion, elevated levels of GGT may be associated with an increased risk of
T2D, but additional studies need to be done in this population.
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Chapter 1: Introduction and Background
Introduction
Gamma-glutamyltransferase (GGT) is elevated in cases of hepatic injury and has
been used to detect chronic alcohol abuse. (Dufour et al., 2000; Hietala, Puukka, Koivisto,
Antilla, & Niemela, 2005; Seitz, 2006; Whitfield, 2001). Many recent studies have
investigated GGT levels and the risk of developing diseases including metabolic syndrome,
type 2 diabetes and cardiovascular disease (Bo et al., 2005; Emdin, Passino, Donato,
Paolicchi, & Pompella, 2002; Emdin, Pompella, & Paolicchi, 2005; Lee et al., 2007). Serum
gamma-glutamyltransferase (GGT) levels that are high but still within the normal limit have
been independently associated with an increased risk for type 2 diabetes in many studies
(Lee, Ha et al., 2003; Nakanishi, Suzuki, & Tatara, 2004; Wannamethee, Sharper, Lennon,
& Whincup, 2005). There has only been one study of hepatic enzymes in Latinos that the
authors know of (Nannipieri et al., 2005). This study investigated the relationship between
liver enzymes (AST, ALT, Alkaline Phosphatase, and GGT), impaired glucose tolerance,
and diabetes. Of the enzymes studied, only raised GGT was an independent predictor of
impaired glucose tolerance or diabetes.
Purpose of the Study
Several researchers have reported that increased GGT is independently associated
with increased risk of type 2 diabetes in Asian and Caucasian populations (André et al.,
2005; Lee, Ha et al., 2003; Lee, Silventoinen, Jacobs, Jusilahti, & Tuomileto, 2004;
Wannamethee et al., 2005). We postulate that a similar increase in risk of T2D associated
with GGT will be found in elderly Latino participants of the Sacramento Area Study on
Aging (SALSA).
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The major aim of this study was to evaluate whether GGT levels measured at
baseline could predict incidence of type 2 diabetes in a large cohort of elderly Mexican
Americans. The authors analyzed baseline laboratory and clinical data from the Sacramento
Area Latino Study on Aging (SALSA) to determine the relative risk of developing type 2
diabetes on the basis of GGT level while adjusting for confounding variables.
Significance of the Study
Predicting an early increased risk of developing type 2 diabetes (T2D) may
encourage a person to make lifestyle changes or obtain treatment, leading to a decreased risk
of diabetes. Additionally, his/her quality and length of life may be improved, decreasing the
overall burden on healthcare systems at the same time.
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Chapter 2: Review of Related Literature
GGT is found in the kidneys, biliary system, pancreas, and intestine (Dufour, 2000).
Briefly, GGT protein catalyzes an enzymatic action, which is the transfer of a glutamyl
residue to an acceptor through the glutamate’s gamma carboxylic acid to an amine or other
amino acid. The most abundant natural substrate is glutathione. Glutathione is extracellular
and cannot pass through the cell membrane. Glutathione can be broken down into 3 amino
acids (including cysteine, which may be deficient in low-protein diets) at the cell membrane
by GGT. These amino acids can be taken up in the cells by the γ-glutamyl cycle.
Glutathione is then reformed in the cells, where it protects cells against oxidants that are
produced during normal metabolism. An increased need for reduced glutathione occurs with
oxidative stress (Lee, Blomhoff, & Jacobs, 2004; Whitfield, 2001; Zhang, Forman, & Choi,
2005).
Research by Aaseth and Støa-Birketvedt (2000) evaluated 10 overweight patients
with poorly controlled type 2 diabetes and discovered that intracellular glutathione was
markedly increased compared to normal controls. Glutathione is a known, powerful
antioxidant that may mediate the inflammatory effect of increased glucose, possibly by
decreasing cytokine production in response to spikes of hyperglycemia (Wright, ScismBacon, & Glass, 2006).
Nonalcoholic fatty liver disease has been linked to a higher prevalence of diabetes
(Bloomgarden, 2005, p. 1519). Oxidative stress resulting from nonalcoholic fatty liver
disease (NAFLD) has been suggested in the mechanisms of insulin resistance, β-cell
dysfunction, poorly-controlled type 2 diabetes, and subsequent complications (Bo et al.,
2005; Robertson, Harmon, Tran, & Poitout, 2004; Thamer et al., 2005; Wright, et al., 2006).
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GGT was first used as a test in the evaluation of liver diseases. It reaches extremely
high levels in patients with biliary obstruction and is a good marker for chronic alcohol
consumption (Lee, Lim, Yang, Ha, & Jacobs, 2005; Seitz, 2006). Research by JimenezAlonso et al. (1983) showed that hyperglycemia itself does not increase the hepatic enzyme
GGT in uncontrolled diabetics. Although most researchers report that GGT appears to be a
marker for oxidative stress, there is some controversy regarding the role that GGT plays in
oxidative stress. Many scientists think that GGT plays an important role in protecting
against oxidative stress by maintaining an adequate supply of intracellular glutathione,
which protects cells against oxidants produced by normal metabolism (Lim et al., 2004;
Meisinger, Löwel, Heier, Schneider, & Thorand, 2005; Zhang et al., 2005). However, others
including Lee, Blomhoff et al. (2004) have noted that increased levels of serum GGT do not
seem to reduce oxidative stress, implying that increased GGT is not a protective mechanism
against oxidative stress.
Numerous studies have found that GGT is not just a marker of alcohol consumption,
but is an independent predictor of many diseases, including cardiovascular diseases, type 2
diabetes, inflammation, and, possibly, underlying oxidative stress (Bo et al., 2005; Emdin et
al., 2002; Emdin et al, 2005; Lee, Jacobs et al., 2003; Sakuta, Suzuki, Yasuda, & Ito, 2005;
Wannamethee et al., 2005; Whitfield, 2001; Yamada et al., 2006).
Meisinger et al. (2005) postulated that possible mechanisms by which GGT is a
marker for increased risk of type 2 diabetes include the following: (a) elevated serum GGT
could indicate excess fat deposits in the liver, which may cause hepatic insulin resistance
and increase the risk of type 2 diabetes by contributing to systemic insulin resistance; (b)
increased GGT is a marker for oxidative stress; and (c) increased GGT may be the
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expression of inflammation. Ortega, Koska, Salbe, Tatatanni, and Bunt (2006) reported that
GGT was a significant predictor of insulin resistance independently of weight, BMI, or
percentage of fat in Pima Indian children.
Many studies have reported an increased risk of type 2 diabetes with increased levels
of GGT. Lee, Ha, et al. (2003) prospectively studied a group of 4,088 healthy, male Korean
workers and found a strong dose response relationship between serum GGT levels at
baseline and incident type 2 diabetes after 4 years of follow up. This relationship was
observed even in nondrinkers. Nakanishi et al. (2004) found that increased serum GGT
increased the risk of incidence of metabolic syndrome and type 2 diabetes in 3,000 middleaged Japanese male office workers. Lee, Silventoinen et al. (2004) evaluated 20,158 Finnish
subjects of both genders, aged 25-64, in a prospective cohort study and found that higher
serum GGT was directly associated with an increased risk of type 2 diabetes. The CARDIA
study (Lee, Jacobs, et al., 2003) recruited 18- to 30-year-old Black and White Americans in
1985-86 and followed them for 15 years. They reported that the risk of type 2 diabetes was
strongly increased with higher normal levels of GGT. In addition, they postulated that this
may be related to oxidative stress. Perry, Wannamethee, & Shaper (1998) examined the
association between GGT levels and the risk of NIDDM in about 7,500 British men (aged
40-59). Their findings suggested that a raised serum GGT level is an independent risk factor
for NIDDM. Wannamethee et al. (2005) conducted a prospective study of 3,500 of the
surviving men from the previous study (now aged 60-79). They reported that both ALT and
GGT were independent predictors of type 2 diabetes in older men and could be useful in
predicting those at high risk of diabetes. Nannipieri et al. (2005) evaluated liver enzymes
(AST, ALT, ALP, and GGT) in 1441 middle-aged (35-64 yrs) male and female participants
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in the population-based Mexico City Diabetes Study at baseline and at 7-year follow-up to
determine the incidence of impaired glucose tolerance (IGT) or type 2 diabetes. They
reported that only increased GGT is an independent predictor of decreased glucose tolerance
or type 2 diabetes. They theorized that GGT elevation may reflect increased hepatic insulin
resistance or oxidative stress. André et al. (2005) studied ALT, AST, and GGT in 2071
French men and 2130 French women 33 to 68 years old and found that only GGT is strongly
associated with increased risk of T2D at 3-year follow-up for both sexes. Meisinger et al.
(2005) studied 1851 male and 1836 female 25 to 64-year-old participants in a populationbased study in Germany (MONICA) and concluded that GGT is an important predictor of
incident type 2 diabetes in both men and women in the general population. Vozarova et al.
(2002) evaluated ALT, AST, and GGT in 451 Pima Indian adults and found that only ALT
is a marker of T2D.
Lee et al. (2007) followed up 3,451 middle-aged male and female participants of the
Framingham Heart Study over a 19-year period and found that increased serum GGT
predicts incidence of metabolic syndrome, cardiovascular disease, and death.
Results from a recent study using data from the third NHANES study (Lee & Jacobs,
2005) showed that all levels of GGT are strongly associated with C-reactive protein (CRP).
CRP is widely recognized as a marker of chronic inflammation, and the association was
present in all populations tested in that study, including Mexican Americans. These results
strongly suggest that GGT is involved in the inflammatory pathway. Figure 1 shows
suspected pathways relating GGT to type 2 diabetes. It is likely that insulin resistance leads
to increased fat deposits in the liver, which cause oxidative stress and inflammation, leading
to type 2 diabetes.
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Figure 1. Diagram of known and theoretical pathways.
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Chapter 3: Research Design and Methods
This study is an evaluation of data obtained from participants of a large, ongoing
cohort study, The Sacramento Area Latino Study on Aging (SALSA). Participants are
Mexican Americans (85%) and other Latinos (primarily Central American) who were aged
60-100 in 1998-99 and resided in a three-county area including Sacramento, California. IRB
approval and written consent was obtained from the participants for interviews, cognitive
testing, and clinical measures including a blood draw and analysis of the samples for
markers relating to diabetes and related diseases at The University of California, Davis
(UCD), at baseline and also at The University of Michigan (UM) IRBMED when the
Coordinating Center moved to UM in 2000. Details of the SALSA study have been
discussed previously (Haan et al., 2003). SALSA participants without diabetes at baseline
and with a GGT result from baseline lab testing were eligible for this study.
Type 2 diabetes was defined by using a modification of the American Diabetes
Association’s (ADA) diabetes diagnosis criteria (Sacks et al., 2002). We modified the
ADA’s criteria (fasting glucose ≥ 126 mg/dL or taking oral diabetes medication or insulin)
by adding the additional criterion of participant report of physician’s diagnosis of diabetes.
Laboratory Methods
In the SALSA study, a fasting blood sample was drawn from the participants into
SST and EDTA tubes during the baseline home visit. One SST tube was transported to the
UC-Davis Medical Center (UCDMC) Clinical Laboratory, where it was centrifuged and
separated, and the resulting serum was assayed for glucose, GGT, and additional tests
included in a chemistry lab panel with a Sequential Multi-channel Analyzer (SMAC). This
testing was usually completed within 4 hours of draw (maximum of 6 hours). Another SST
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was separated into several serum tubes and frozen at -70 °C. One serum tube was shipped
for fasting insulin testing with a radioimmunoassay method (ARUP Laboratories, Salt Lake
City, Utah). We tested an additional frozen serum sample for high-sensitivity CRP at a later
date, using the method described in the follow-up laboratory measures section.
Follow-up laboratory measures. No blood samples were taken in the second year of
follow-up. Blood samples taken at the third-year follow-up visit and later (2002-2006) were
tested at the Chemistry Lab of the Michigan Diabetes Research and Training Center
(MDRTC). Glucose and lipid assays were performed on a Cobas Mira Chemistry Analyzer
from Roche Diagnostics Corporation, Indianapolis, IN, USA. Glucose was tested with a
hexokinase method. Lipid testing included Total Cholesterol, HDL Cholesterol, and
Triglycerides. The LDL result was calculated, but if the Triglyceride level was greater than
400mg/dl, the lab performed a direct assay for LDL with the LDL Direct Liquid Select
reagent from Equal Diagnostics and the Cobas Mira instrument. The laboratory determined
fasting insulin levels on serum samples by using a double-antibody radioimmunoassay with
a 125I-Human insulin tracer (Linco Research, Billerica, MA) and hs-CRP level by using a
latex-enhanced, immunoturbidimetric method and the High Sensitivity CRP kit (Genzyme
Diagnostics, Cambridge, MA, formerly Equal Diagnostics) that is automated for use on the
Cobas Mira Chemistry Analyzer (Roche Diagnostics Corporation).
Other covariates. The Waist-Hip Ratio (WH) was calculated as WH = (Waist, inch /
Hip measure, inch). Body Mass Index (BMI) was calculated as weight in pounds and height
in inches according to the following formula: BMI = (Weight in Pounds / (Height in inches)
x (Height in inches) ) x 703. We calculated an estimate of insulin resistance with a
modification of the HOMA-IR model that uses a single fasting glucose and insulin result.
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We modified the standard formula to allow us to use glucose values in mg/dL rather than SI
units. This modification yielded the following formula: HOMA-IR = (Fasting insulin,
mU/ml * Fasting Glucose, mg/dl) / 405). (Bonora et al., 2000; Wallace, Levy, & Matthews,
2004; JAMA, 2001; RCMAR website, 2006.)
Statistical Analysis
All analyses were done with SAS 9.1 statistical software (SAS Institute Inc., Cary,
NC, USA). In multivariate models, we adjusted for diabetes risk factors. Variables with nonnormal distributions were log transformed. GGT as a continuous variable was used in the
reported analysis. GGT quintiles were also examined to determine the significance between
high normal levels of GGT and lower levels in a method similar to that used in many
published studies, but there was no significant difference in results.
Variable data are presented as means. The means, medians, and proportions of
participant characteristics, risk factors, and lab results were calculated from baseline data.
All analyses were performed separately on men and women because some studies have
shown that GGT is only predictive of T2D in males. There was no difference when the
hazard models were analyzed by gender, so the data are not shown. Additionally, selfreported kidney problems were significantly related to T2D but did not alter the results when
the Proportional Hazard model was adjusted for them (data not shown).
The relationship between GGT and other variables was analyzed with a Spearman
correlation matrix. Significant covariates (α = 0.05) that were tested in the incidence models
included height, weight, waist circumference, HDL, LDL, Triglycerides, fasting glucose,
fasting insulin, HOMA-IR (Insulin Resistance), hs-CRP, AST, Alkaline Phosphatase, and
Total Bilirubin.
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To calculate incidence rates, we used the incidence density approach. The length of
follow-up was calculated as days from baseline exam to diabetes diagnosis or date of last
follow-up exam. The date of diabetes diagnosis was the date that any of the following
occurred: (a) participant reported that a physician diagnosed them with diabetes; (b)
participant’s fasting glucose result was ≥ 126 mg/dL; and (c) participant reported starting to
take a glucose-lowering medication. Participants were censored after their last examinations.
We used the PHREG procedure in the SAS 9.1 statistical package (SAS Institute Inc., Cary,
NC, USA) to generate Cox proportional hazard models and calculate the multivariateadjusted hazard ratios.
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Chapter 4: Results
Table 1 shows characteristics of the study population at baseline. There was a
statistically significant difference in the means between the group of participants who
developed incident diabetes and the group that never developed diabetes for the variables of
age, smoking status, and self-reported kidney problems. The participants who developed
diabetes were younger at age of enrollment, less likely to be smokers, and more likely to
have self-reported kidney problems. There were no differences between diabetics and
nondiabetics for sex, education level, alcohol use (beer, wine, or hard liquor were tested
separately), self-reported liver or gallbladder problems, or nativity.
Results of clinical measures obtained at baseline examination are shown in Table 1
on the next page. There were no differences in height or waist-to-hip ratio between diabetics
and nondiabetics. Compared to nondiabetics, diabetics had larger hip and waist
circumferences, higher BMIs, and greater weight.
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Table 1
Characteristics of the Study Population at Baseline
Characteristic

Whole group

Incident DM

DM

(n = 1203)
70.8
(SD = 7.2, n = 1203)

(n = 178 )
69.5
(SD = 6.3, n = 178)

(n = 1025 )
71.0
(SD = 7.3, n = 1025)

40.7% (n = 490)

46.6% (n = 83)

39.7% (n = 407)

59.3% (n = 713)

53.4% (n = 95)

60.3% (n = 618)

7.3
(SD = 5.3, n = 1193)

7.39
(SD = 5.6, n = 175)

7.29
(SD = 5.5, n = 1018)

0.8155 ‡

12.3% (n = 146)

7.4% (n = 13)

13.1% (n = 133)

0.0015 †

- Past (%)

40.8% (n = 485)

52.6% (n = 92)

38.7% (n = 393)

- Never (%)

47.0% (n = 559)

40.0% (n = 70)

48.2% (n = 489)

Current beer use (%)

46.6% (n = 555)

46.9% (n = 82)

46.6% (n = 473)

0.941 †

Current wine use (%)

40.5% (n = 482)

41.2% (n = 72)

40.4% (n = 410)

0.8522 †

Current hard liquor
use (%)

30.9% (n = 368)

31.4% (n = 55)

30.8% (n = 313)

0.8758 †

Liver problems (%)

2.81% (n = 33)

4.65% (n = 8)

2.50% (n = 25)

0.1146 †

Kidney problems (%)

6.18% (n = 72)

9.94% (n = 17)

5.53% (n = 55)

0.027 †

Gallbladder problems
(%)

17.87% (n = 210)

22.41% (n = 39)

17.08% (n = 171)

0.0902 †

45.9% (n = 547)

46.9% (n = 82)

45.8% (n = 466)

0.2013†

- Born in Mexico

47.7% (n = 569)

49.7% (n = 87)

47.3% (n = 481)

-Born in Other
Country

6.45% (n = 77)

3.43% (n = 6)

6.97% (n = 71)

Waist-to-hip ratio
mean (in)

0.9
(SD = 0.09, n = 1082)

0.91
(SD = 0.09, n = 166)

0.9
(SD = 0.09, n=916)

0.0713

Hip circumference,
inches (mean)

41.7
(SD = 4.7, n = 1083)

42.9
(SD= 5.4, n = 167)

41.5
(SD = 4.6, n = 916)

< 0.0019

‡

Waist circumference,
inches (mean)

37.38
(SD = 5.2, n = 1088)

38.86
(SD = 5.6, n = 168)

37.11
(SD = 5.1, n = 920)

< 0.0001

‡

Height, ft (mean)

5.22
(SD = 0.33, n = 1091)

5.24
(SD = 0.33, n = 169)

5.22
(SD = 0.33, n = 922)

0.5913

Weight, lbs (mean)

163
(SD = 34, n=1086)

173
(SD = 34, n = 169)

160
(SD = 33, n = 917)

< 0.0001

‡

BMI (mean)

29.1
(SD = 5.6, n = 1084)

30.7
(SD = 5.3, n = 169)

28.7
(SD = 5.6, n = 915)

< 0.0001

‡

Age at enrollment, yrs
(mean)
Sex (%)
-Male
-Female
Education in yrs
(mean)
Smoking status
- Current (%)

Nativity (%)

P value
( difference of
the means)
< 0.0035 ‡
0.0827 †

- Born in USA

† Chi-squared test
‡ t test
SD = standard deviation
n = total number of observations
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‡

‡

Baseline laboratory test results are shown in Table 2. With the exception of HDL, the
diabetic group was higher on every measure, including glucose, insulin, insulin resistance,
hs-CRP, lipid measures, and liver enzymes. HDL was lower in diabetics than in
nondiabetics.
Table 2
Baseline Laboratory Test Results
Whole group
mean
(n = 1193)
93.70
(n = 1083)

Incident DM
mean
(n = 189)
103.42
(n = 167)

___
DM
mean
(n = 1004)
91.93
(n = 916)

( difference of the
means)

Fasting insulin,
mU/ml

10.74
(n = 1074)

12.57
(n = 165)

10.40
(n = 909)

< 0.0001

CRP, mg/L
(High sensitivity)

5.25
(n = 1041)

5.46
(n = 162)

5.21
(n = 879)

< 0.0001*

Insulin resistance
(HOMA-IR)

2.439
(n = 1070)

3.285
(n = 165)

2.285
(n = 905)

< 0.0001*

AST, U/L

23.68
(n = 1082)

24.57
(n = 167)

23.52
(n = 915)

< 0.0001*

Alkaline
phosphatase, U/L

80.26
(n = 1082)

82.53
(n = 167)

79.85
(n = 915)

< 0.0001*

GGT, U/L

28.80
(n = 1069)

33.84
(n = 167)

27.86
(n = 902)

< 0.0001*

Total bilirubin,
mg/dL

0.779
(n = 1080)

0.801
(n = 167)

0.775
(n = 913)

< 0.0001*

Total cholesterol,
mg/dL

214.2
(n = 1085)

206.5
(n = 167)

215.6
(n = 918)

< 0.0001

HDL, mg/dL

53.65
(n = 1085)

50.50
(n = 167)

54.23
(n = 918)

< 0.0001*

LDL, mg/dL

125.8
(n = 1084)

120.0
(n = 167)

126.9
(n = 917)

< 0.0001

Triglycerides,
mg/dL

173.7
(n = 1084)

180.1
(n = 167)

172.5
(n = 917)

< 0.0001*

Lab test

Fasting glucose,
mg/dL

† Chi-squared test
‡ t test
* used transformed data for t test
n = total number of observations
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P value ‡

< 0.0001

A total of 6,187 person years of follow-up were analyzed. Table 3 below shows the
incidence rates of type 2 diabetes in the study population overall and by gender and age. The
highest crude rates were among men and women aged 70-79. The oldest participants (80+
years) had the lowest incidence of diabetes.
Table 3
Incidence Rate of Type 2 Diabetes by Gender and Age at Diagnosis
Gender and age
Number of
Crude rate per
at diagnosis
incident cases Person-years
1,000 PY
Men
< 60-69
28
894.75
31.29
70-79
48
1092.39
43.94
80 +
7
464.87
15.06
Total men
83
2452.01
33.85
Women
< 60-69
70-79
80 +
Total women

33
55
7
95

1292.43
1828.92
613.46
3734.81

25.53
30.07
11.41
25.44

61
103
14
178

2187.18
2921.31
1078.33
6186.82

27.89
35.26
12.98
28.77

All
< 60-69
70-79
80 +
Total all

Table 4 shows the association of baseline GGT and risk for incident diabetes in a
series of Cox models with progressive adjustment for covariates. In model 1, increased GGT
was associated with a 40% increased risk of developing type 2 diabetes. After adjustment for
age and gender (model 2), the RR was still significant. Adjustment for covariates in model 3
and model 4 did not affect the association between GGT and T2D. Adjustment for each
covariate except fasting glucose, HOMA-IR, and/or fasting insulin was done, and none
reduced the significance. When fasting serum glucose, HOMA-IR, or fasting serum insulin
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was introduced into the model (Model 5), the association was attenuated by nearly 20% and
was no longer significant. A test for interaction between GGT and glucose was not
significant (p = 0.25).
Table 4
GGT and Adjusted Relative Risk of Type 2 Diabetes Incidence
95% Confidence
GGT result
Hazard ratio
limits
lower
upper
Model 1
1.41
1.15
1.74

P value
0.001

Model 2

1.38

1.11

1.71

0.004

Model 3

1.42

1.14

1.77

0.002

Model 4

1.33

1

1.75

0.04

Model 5

1.13

0.84

1.51

0.426

Notes.
Model 1 unadjusted
Model 2 Model 1 + adj for age and sex
Model 3 Model 2 + adj for smoking and alcohol
Model 4 Model 3 + adj for BMI, HDL, LDL, triglycerides, AST, alkaline
phosphatase, hs-CRP, and, total bilirubin
Model 5 Model 4 + adj for glucose
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Chapter 5: Conclusions, Limitations, and Recommendations for Further Research
Glucose was highly predictive of type 2 diabetes in this study, and it reduced the
association between GGT and type 2 diabetes. The insulin resistance test measure (HOMAIR) is calculated with the glucose result, so it reduced the association as well. GGT is highly
correlated with glucose, insulin, and insulin resistance, so it is likely that the effect of GGT
on T2D is through the insulin resistance mechanism.
There were several limitations to this study. One limitation of this study is that we
only had fasting serum samples available rather than plasma samples as recommended by
the ADA. Fasting plasma sample results would have yielded a more stable measure because
there was a time lag between blood draw and processing. Although serum has been reported
to have glucose concentrations 5% higher than those of plasma, if the cells stay in contact
with the serum, as in our study, the rate of glucose disappearance will be higher in serum
and can be affected by other factors (Ladenson, Tsai, Michael, Kessler, & Joist, 1974).
Insulin resistance could affect the breakdown rate of glucose between the groups, causing
the glucose level in the incident diabetic group to remain higher and appear highly
predictive of T2D. It is possible that the significant relationship that we saw between GGT
and fasting serum glucose resulted from increased concentrations of GGT in the pancreases
of this population. Adjustment for self-reported kidney or liver problems did not change the
results. The study population only included elderly Mexican Americans, so these results
may indicate that GGT levels are lower in Mexican Americans or the elderly. The follow-up
period used for one of the positive studies (Perry et al., 1998) discussed earlier was more
than double the length of our follow-up period of 5 years.
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Although there was no interaction between glucose and GGT level, the glucose level
was so highly predictive of T2D that we postulate that GGT may be on the pathway between
glucose and T2D, potentially beginning with fatty liver disease or insulin resistance, causing
oxidative stress and leading to increased insulin resistance, more fatty liver deposits,
increased glucose, and ultimately, T2D. Figure 2 below shows the suspected pathway
between oxidative stress, increased glucose, increased GGT, and type 2 diabetes.
In conclusion, GGT appears to be a predictor of risk of developing type 2 diabetes,
but adjustment for fasting glucose attenuated the risk in our study population. This may be
due to differences in amounts of GGT in the organs or GGT function and metabolism in our
study population or, possibly, study limitations as described previously. It would be
important to repeat this analysis in all ages of this population group to further characterize
the relationship of GGT, oxidative stress, insulin resistance, and type 2 diabetes in Mexican
Americans. Additionally, analyzing data from a lengthened follow-up period would yield
more information about this relationship.

Fatty liver disease
OR

Oxidative stress Æ increased GlucoseÆ increased GGT Æ T2D

Insulin Resistance

Figure 2. Pathway showing possible GGT relationship to glucose.
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